FrancophonIA/ELRC3.0 huggingface dataset:
English: The patient information should contain the following key elements: m) Key signs and symptoms of serious adverse events associated with the intravitreal injection procedure including endophthalmitis, increased intraocular pressure, retinal injury, intraocular haemorrhage, traumatic cataract, hypersensitivity and injection of excess volume n) When to seek urgent attention from the health care provider
Slovenian: Informacije za bolnika morajo vključevati naslednje ključne elemente o: m) ključnih znakih in simptomih resnih neželenih dogodkov, povezanih s postopkom intravitrealnega injiciranja in vključujejo endoftalmitis, zvišanje očesnega tlaka, poškodbo mrežnice, krvavitev v oko, travmatsko katarakto, preobčutljivost in injiciranje odvečnega volumna n) tem, kdaj naj bolnik poišče urgentno pomoč zdravstvenega delavca.
English: At doses below 0.5 mg/eye, pegaptanib plasma concentrations do not likely exceed 10 ng/ml.
Slovenian: Če so odmerki manjši od 0,5 mg/oko, ni verjetno, da bi koncentracija pegaptaniba v plazmi presegla 10 ng/ml.
English: • increased sensitivity to light, appearance of flashing lights
Slovenian: • večja občutljivost za svetlobo, bliskanje pred očmi
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Slovenian: To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni „brez natrija“.
English: Macugen is used for the treatment of the wet form of age-related macular degeneration (AMD).
Slovenian: Zdravilo Macugen uporabljamo za zdravljenje vlažne oblike starostne degeneracije makule (AMDage-related macular degeneration).
English: Marketing Authorisation Holder: PharmaSwiss Česká republika s.r.o.
Slovenian: Imetnik dovoljenja za promet z zdravilom: PharmaSwiss Česká republika s.r.o.
English: Injecting the entire volume of the prefilled syringe could result in overdose (see section 4.8 and 4.9).
Slovenian: Injiciranje celotnega volumna napolnjene injekcijske brizge lahko povzroči preveliko odmerjanje (glejte poglavji 4.8 in 4.9).
English: In humans, the average ± standard deviation apparent plasma half-life of pegaptanib after a 3 mg (10-times the recommended dose) monocular dose is 10 ± 4 days.
Slovenian: Pri človeku je navidezni razpolovni čas pegaptaniba v plazmi (povprečje ± standardni odklon) po odmerku 3 mg (kar je 10-kratni priporočeni odmerek) v eno oko 10 ± 4 dni.
English: Overdosing with increased injection volume (e.g. when the excess volume in the pre-filled syringe is not expelled before injection) may elevate intraocular pressure (see section 4.8).
Slovenian: Preveliko odmerjanje, ki je posledica injiciranja večje količine injekcijske raztopine (npr. kadar pred injiciranjem ne odstranimo odvečnega volumna v napolnjeni injekcijski brizgi), lahko povzroči zvišanje očesnega tlaka (glejte poglavje 4.8).
English: Therefore, the perfusion of the optic nerve head and intraocular pressure should be monitored.
Slovenian: Zato je treba nadzirati perfundiranost glave vidnega živca in očesni tlak.
English: The selective inhibition in animals with pegaptanib proved as effective at suppressing pathological neovascularisation as pan-VEGF inhibition, however pegaptanib spared the normal vasculature whereas pan-VEGF inhibition did not.
Slovenian: Selektivno zavrtje s pegaptanibom je patološko neovaskularizacijo pri živalih zavrlo enako učinkovito kot splošno zavrtje VEGF, le da pegaptanib pri tem ni prizadel normalnega žilja, medtem ko ga splošno zavrtje VEGF je.
English: Each carton contains one pre-filled syringe in a pouch (single dose pack).
Slovenian: Ena škatla vsebuje eno napolnjeno injekcijsko brizgo v vrečki (enoodmerno pakiranje).
English: Macugen is administered as a single injection (0.3 mg) into your eye at intervals of 6 weeks (i.e. 9 times per year).
Slovenian: Zdravilo Macugen boste dobili v oko z enkratnim injiciranjem (0,3 mg) vsakih 6 tednov (tj. 9-krat na leto).
English: Occasionally, an infection or bleeding in the eye can occur after Macugen injection (in the next two weeks).
Slovenian: Občasno se lahko po injiciranju zdravila Macugen (v naslednjih dveh tednih) pojavi okužba ali krvavitev v očesu.
English: The recommended dose is 0.3 mg pegaptanib, equivalent to 90 microliters, administered once every six weeks (9 injections per year) by intravitreal injection into the affected eye.
Slovenian: Priporočeni odmerek je 0,3 mg pegaptaniba, kar ustreza 90 mikrolitrom, in se aplicira enkrat na šest tednov (9 injekcij na leto), in sicer z injiciranjem v steklovino bolnega očesa.
English: Pegaptanib is a pegylated modified oligonucleotide that binds with high specificity and affinity to extracellular Vascular Endothelial Growth Factor (VEGF165) inhibiting its activity.
Slovenian: Pegaptanib je pegiliran modificiran oligonukleotid, ki se zelo specifično in z veliko afiniteto veže na zunajcelični žilni endotelijski rastni faktor (VEGF165; VEGF - vascular endothelial growth factor) in zavre njegovo delovanje.
English: • blood in your eye, discoloured eye, deposit eye
Slovenian: • kri v očesu, obarvanje očesa, odložki v očesu
English: Uncommon hypertension, aortic aneurysm
Slovenian: Žilne bolezni občasni hipertenzija, anevrizma aorte
English: SLOWLY depress the plunger to eliminate all the bubbles and to expel the excess drug so that the top edge of the 3rd rib on the plunger stopper aligns with the pre-printed black dosing line (See Figure 2, below).
Slovenian: POČASI potisnite bat, da odstranite vse zračne mehurčke in odvečni volumen zdravila, tako da je zgornji rob tretjega rebra na gumijastem tesnilu poravnan z natisnjeno črno odmerno črto (glejte sliko 2 spodaj).
English: Macugen solution for injection is supplied in a single dose pack.
Slovenian: Zdravilo Macugen raztopina za injiciranje je na voljo v enoodmernem pakiranju.
English: Intravitreal injection procedures are associated with a risk of endophthalmitis; in Macugen clinical trials, the incidence of endophthalmitis was 0.1% per injection (see section 4.2).
Slovenian: V kliničnih preskušanjih zdravila Macugen je bila pogostnost endoftalmitisa 0,1 % na injekcijo (glejte poglavje 4.2).
English: In rabbits, pegaptanib is eliminated as parent drug and metabolites primarily in the urine.
Slovenian: Pri kuncih se pegaptanib izloča kot matično zdravilo in v obliki presnovkov, predvsem v urin.
English: There are limited data on safety in patients with prior history of stroke or transient ischaemic attacks.
Slovenian: Podatki o varnosti pri bolnikih z anamnezo možganske kapi ali prehodnimi ishemičnimi napadi so omejeni.
English: Macugen is a solution which is injected into the eye. Pegaptanib, the active substance of this medicine, inhibits the activity of the factor involved in the abnormal formation of new blood vessels in the eye, known as Vascular Endothelial Growth Factor165 (VEGF165).
Slovenian: Pegaptanib, zdravilna učinkovina v tem zdravilu, zavira aktivnost faktorja, ki sodeluje pri tvorbi novih krvnih žil v očesu, poznanega kot žilni endotelijski rastni faktor (VEGF165).
English: Uncommon asthenopia, blepharitis, conjunctivitis allergic, corneal deposits, eye haemorrhage, eyelids pruritus, keratitis, vitreous haemorrhage, pupillary reflex impaired, corneal abrasion, retinal exudates, eyelid ptosis, retinal scar, chalazion, corneal erosion, decreased intraocular pressure, injection site reaction, injection site vesicles, retinal detachment, corneal disorder, retinal artery occlusion, retinal tear, ectropion, eye movement disorder, eyelid irritation, hyphaema, pupillary disorder, iris disorder, ocular icterus, anterior uveitis, deposit eye, iritis, optic nerve cupping, pupillary deformity, retinal vein occlusion, and vitreous prolapse
Slovenian: Očesne bolezni zelo pogosti vnetje sprednjega prekata, bolečina v očesu, zvišan očesni tlak, točkasti keratitis, motnjave v steklovini in delci v pogosti nenormalen občutek v očesu, katarakta, veznična krvavitev, veznična hiperemija, edem veznice, konjunktivitis, distrofija roženice, okvara roženičnega epitelija, obolenja roženičnega epitelija, edem roženice, suho oko, endoftalmitis, izcedek iz očesa, vnetje očesa, draženje očesa, srbenje očesa, pordelost očesa, oteklost očesa, edem veke, močnejše solzenje, degeneracija makule, midriaza, nelagodje v očesu, očesna hipertenzija, periorbitalni hematom, fotofobija, fotopsija, mrežnična krvavitev, zamegljen vid, zmanjšanje ostrine vida, motnje vida, odstop steklovine in obolenja steklovine občasni astenopija, blefaritis, alergijski konjunktivitis, odložki v roženici, očesna krvavitev, srbenje vek, keratitis, krvavitev v steklovino, okvarjen zenični refleks, abrazija roženice, mrežnični eksudati, ptoza veke, mrežnična brazgotina, halazij, erozija roženice, znižan očesni tlak, reakcija na mestu injiciranja, mehurčki na mestu injiciranja, odstop mrežnice, obolenja roženice, zapora mrežnične arterije, pretrganje roženice, ektropij, motnja gibanja očesa, draženje veke, hifema, obolenja zenice, obolenja šarenice, očesni ikterus, sprednji uveitis, očesni odložki, iritis, uvlek vidnega živca, deformacija zenice, zapora mrežnične vene in prolaps
English: A mean maximum plasma concentration of about 80 ng/ml occurs within 1 to 4 days after a 3 mg monocular dose in humans.
Slovenian: Povprečna največja plazemska koncentracija približno 80 ng/ml se pri človeku pojavi v 1-4 dneh po odmerku 3 mg v eno oko.
English: The pack is supplied without a needle.
Slovenian: Pakiranje ne vsebuje igle.
English: What Macugen looks like and contents of the pack
Slovenian: Izgled zdravila Macugen in vsebina pakiranja
English: Macugen works by inhibiting the growth of these abnormal blood vessels and by stemming the bleeding and leakage.
Slovenian: Zdravilo Macugen zavira rast nenormalnih žil in ustavlja krvavitev in pronicanje tekočine.
English: • inflammation of your eye or of the outer surface of the eye
Slovenian: • vnetje očesa ali zunanje površine očesa
English: In the 40 mg/kg/day group, pegaptanib concentrations in the amniotic fluid were 0.05% of the maternal plasma levels.
Slovenian: V skupini, ki je dobivala 40 mg/kg/dan, so bile koncentracije pegaptaniba v amnijski tekočini 0,05 % plazemske koncentracije pri samicah.
English: Macugen therapy administered to both eyes concurrently has not been studied.
Slovenian: Zdravljenje z zdravilom Macugen na obeh očesih hkrati ni raziskano.
English: Macugen should be inspected visually for particulate matter and discoloration prior to administration (see section 6.6).
Slovenian: Pri zdravilu Macugen je treba pred uporabo vizualno preveriti prisotnost delcev in obarvanje (glejte poglavje 6.6).
English: Intravitreal use
Slovenian: za intravitrealno uporabo
English: • bleeding that occurs around the eye (periorbital bleeding)
Slovenian: • krvavitev v okolici očesa (periorbitalna krvavitev)
English: • increased pressure inside the eye
Slovenian: • zvišan tlak v očesu
English: The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4).
Slovenian: Pred izvedbo intravitrealnega postopka je treba skrbno preučiti bolnikovo anamnezo preobčutljivostnih reakcij (glejte poglavje 4.4).
English: If there are bubbles, the syringe should be gently tapped with a finger until the bubbles rise to the top of the syringe.
Slovenian: Če so, s prstom rahlo trkajte po injekcijski brizgi, dokler ne izplavite mehurčkov na vrh.
English: Before expelling air bubble and excess drug
Slovenian: Pred odstranitvijo zračnih mehurčkov in odvečnega zdravila
English: The injection is given into the vitreous of the eye, which is the jelly-like substance inside the eye.
Slovenian: Zdravnik bo injekcijo dal v očesno steklovino, zdrizasto snov v notranjosti očesa.
English: Uncommonly, an infection in the internal portion of the eye can occur after two weeks following Macugen treatment.
Slovenian: Občasno se lahko v dveh tednih po zdravljenju z zdravilom Macugen razvije okužba notranjega dela očesa.
English: If you have an active or suspected infection in or around the eye.
Slovenian: - če imate okužbo v očesu ali njegovi okolici ali sum nanjo.
English: If you are pregnant discuss this with your doctor before treatment with Macugen.
Slovenian: Če ste noseči, se pred zdravljenjem z zdravilom Macugen posvetujte z zdravnikom.
English: Verteporfin photodynamic therapy (PDT) was permitted in patients with predominantly classic lesions at the discretion of the investigators.
Slovenian: Pri bolnikih s pretežno klasičnimi lezijami je bila dovoljena fotodinamična terapija z verteporfinom (PDT - photodynamic therapy) po presoji raziskovalcev.
English: After intravitreal and intravenous administrations of radiolabeled pegaptanib to rabbits, the highest concentrations of radioactivity (excluding the eye for the intravitreal dose) were obtained in the kidney.
Slovenian: Po intravitrealni in intravenski aplikaciji radioaktivno označenega pegaptaniba kuncem je zdravilo doseglo največjo koncentracijo v ledvicah (če izvzamemo oko pri intravitrealni uporabi).
English: Overfill volume
Slovenian: Odvečni volumen
English: The adverse reactions are listed by system organ class and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and not known (cannot be estimated from the available data).
Slovenian: V nadaljevanju opisani podatki o varnosti povzemajo vse neželene učinke, potencialno povezane s postopkom injiciranja in z zdravilom, pri 295 bolnikih v skupini, ki je dobivala odmerek 0,3 mg. Neželeni učinki so našteti po organskem sistemu in pogostnosti: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100) in neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
English: Cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in patients within several hours after administration of pegaptanib along with various medicinal products administered as part of the injection preparation procedure (see sections 4.2 and 4.4).
Slovenian: Pri bolnikih so v nekaj urah po uporabi pegaptaniba skupaj z različnimi zdravili, ki so del postopka priprave na injiciranje, poročali o primerih anafilaksije/anafilaktoidnih reakcij, vključno z angioedemom (glejte poglavji 4.2 in 4.4).
English: Please seek immediate medical help if you experience any of the following soon after the injection: sudden onset of breathing difficulty or wheezing, swollen mouth, face, hands or feet, itching skin, fainting, rapid pulse, stomach cramps, nausea, vomiting or diarrhoea.
Slovenian: Če doživite karkoli od navedenega kmalu po injiciranju, prosimo poiščite takojšnjo medicinsko pomoč: nenaden nastop težav z dihanjem ali piskajoče dihanje, otekanje ust, obraza, rok ali nog, srbenje kože, omedlevico, hiter utrip, želodčne krče, slabost s siljenjem na bruhanje, bruhanje ali drisko.
English: Reports from post-marketing experience are included in italics.
Slovenian: Podatki iz obdobja trženja zdravila so navedeni v ležeči pisavi.
English: Package Leaflet: Information for the patient
Slovenian: • Informacije za bolnika
English: The systemic exposure to pegaptanib is expected to be very low after ocular administration.
Slovenian: Pričakovana sistemska izpostavljenost pegaptanibu po očesni aplikaciji je zelo majhna.
English: • irritation and inflammation of the skin, hair colour changes, rash, itching,
Slovenian: • draženje in vnetje kože, spremembe barve las, izpuščaj, srbenje
English: • inflammation of the central part of the surface of the eye (keratitis)
Slovenian: • vnetje osrednjega dela površine očesa (keratitis)
English: • Physician safety brochure
Slovenian: • Brošuro z informacijami o varnosti zdravila, namenjeno zdravnikom
English: Macugen has not been adequately studied in patients with severe renal impairment.
Slovenian: Zdravila Macugen niso zadostno preučili pri bolnikih s hudo ledvično okvaro.
English: • inflammation of the eye (iritis)
Slovenian: • vnetje šarenice (iritis)
English: 4.7 Effects on ability to drive and use machines Macugen has a minor influence on the ability to drive and use machines due to the possible temporary visual blurring after administration of Macugen by intravitreal injection.
Slovenian: Zdravilo Macugen ima blag vpliv na sposobnost vožnje in upravljanja strojev, saj je po injiciranju zdravila Macugen v steklovino možna prehodna zameglitev vida.
English: In animals, pegaptanib is slowly absorbed into the systemic circulation from the eye after intravitreal administration.
Slovenian: Po intravitrealni aplikaciji se pegaptanib pri živalih iz očesa počasi absorbira v sistemski obtok.
English: After expelling air bubble and excess drug
Slovenian: Po odstranitvi zračnih mehurčkov in odvečnega zdravila
English: The physician safety brochure should contain the following key elements: a) The intravitreal procedure as it was performed in the pivotal clinical studies, along with any technical improvements b) Use of povidone iodine c) Performing lid scrubs d) Use of anaesthetic to ensure patient comfort e) Sterile techniques to minimize the risk of infection f) Use of antibiotics g) Techniques for the intravitreal injection h) Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis,
Slovenian: Brošura z informacijami o varnosti zdravila, namenjena zdravnikom, mora vključevati naslednje ključne elemente o: a) intravitrealnem postopku, kot so ga opravljali v ključnih kliničnih študijah, skupaj s kakršnimikoli tehničnimi izboljšavami b) uporabi povidon joda c) postopku čiščenja vek d) uporabi anestetika za preprečevanje neprijetnosti postopka za bolnika e) sterilnih tehnikah za zmanjševanje tveganja okužbe f) uporabi antibiotikov g) tehnikah intravitrealnega injiciranja h) ključnih znakih in simptomih neželenih dogodkov, ki so povezani z intravitrealnim injiciranjem in vključujejo endoftalmitis, zvišanje očesnega tlaka, poškodbo mrežnice, krvavitev v oko, travmatsko katarakto, preobčutljivost in injiciranje odvečnega volumna i) zdravljenju očesnega tlaka j) zdravljenju endoftalmitisa k) razumevanju dejavnikov tveganja za nastanek endoftalmitisa l) poročanju o resnih neželenih dogodkih (opomnik)
English: No special considerations are needed in patients with creatinine clearance above 20 ml/min who are treated with the recommended dose of pegaptanib sodium 0.3 mg.
Slovenian: Pri bolnikih, ki imajo očistek kreatinina nad 20 ml/min in dobivajo priporočeni odmerek 0,3 mg pegaptaniba, niso potrebni posebni previdnostni ukrepi.
English: Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
English: Following the injection, transient increases in intraocular pressure were seen in Macugen treated patients.
Slovenian: Po injiciranju so pri bolnikih, zdravljenih z zdravilom Macugen, zabeležili prehodno zvišanje očesnega tlaka.
English: What Macugen contains
Slovenian: Kaj vsebuje zdravilo Macugen
English: Immediate (on the day of injection) and delayed intravitreous haemorrhages may occur following pegaptanib injections (see section 4.2).
Slovenian: Po injiciranju pegaptaniba se lahko pojavijo takojšnje (na dan injiciranja) in zapoznele intravitrealne krvavitve (glejte poglavje 4.2).
English: Macugen should only be administered by ophthalmologists experienced in intravitreal injections.
Slovenian: Zdravilo Macugen sme aplicirati le oftalmolog, ki ima izkušnje z injiciranjem v steklovino.
English: In the clinical trial, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in intravitreal VEGF inhibitor-treated patients.
Slovenian: V kliničnem preskušanju se je skupna pogostnost izvenočesnih krvavitev, neželenega dogodka, ki bi bil lahko povezan s sistemskim zavrtjem VEGF (žilnega endotelijskega rastnega faktorja), rahlo povečala pri bolnikih po intravitrealni uporabi zaviralcev VEGF, vendar pa med različnimi krvavitvami ni bilo doslednega vzorca.
English: In advanced disease the initiation and continuation of Macugen therapy should consider the potential for useful vision in the eye.
Slovenian: V primeru napredovale bolezni je treba pri odločitvi za začetek ali nadaljevanje zdravljenja z zdravilom Macugen upoštevati potencial uporabnega vida na očesu.
English: Mean Change in Visual Acuity Over Time; Year 1; ITT (LOCF)
Slovenian: Povprečna sprememba ostrine vida (VA - visual acuity) v 1. letu; populacija, ki so jo želeli zdraviti (ITT - intent-to-treat) (zadnje izvedeno opazovanje (LOCF - last observation carried forward))
English: • small deposits on the eye or on the surface of the eye (cornea), deposits in the back of the eye,
Slovenian: • majhni odložki na očesu ali površini očesa (roženici), odložki na zadnjem delu očesa
English: Cardiac disorders Uncommon palpitations
Slovenian: Srčne bolezni občasni palpitacije
English: Dosing line and top edge of 3rd rib aligned
Slovenian: Odmerna črta in zgornji rob tretjega rebra sta poravnana
English: A 27 or 30 G x ½ inch needle should be attached to the luer lock adaptor, to allow the administration of the medicinal product (see Figure 1, below).
Slovenian: Za aplikacijo zdravila morate na nastavek „luer lock“ namestiti iglo 27 G ali 30 G (glejte sliko 1 spodaj).
English: Macugen is not recommended during breast-feeding.
Slovenian: Uporaba zdravila Macugen med dojenjem ni priporočljiva.
English: Pegaptanib pharmacokinetics have not been studied in patients with hepatic impairment.
Slovenian: Farmakokinetike pegaptaniba pri bolnikih z okvaro jeter niso preučevali.
English: Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition.
Slovenian: Arterijski trombembolični dogodki sodijo med neželene dogodke, ki bi lahko bili povezani s sistemskim zavrtjem VEGF.
English: Each pack contains a pouch in a carton, containing a pre-filled syringe, Type I glass, filled with 0.250.27 ml of solution, sealed with an elastomeric plunger stopper and a pre-attached plunger rod, held by a plastic clip.
Slovenian: Ena škatla vsebuje vrečko z napolnjeno injekcijsko brizgo iz stekla tipa I, napolnjeno z 0,25-0,27 ml raztopine, z že vstavljenim potisnim batom in gumijastim tesnilom.
English: These new blood vessels may bleed and leak fluid, causing the macula to bulge or lift up, thus distorting or destroying central vision.
Slovenian: Makula se zato izboči ali dvigne in tako popači ali uniči osrednji vid.
English: • retinal artery occlusion
Slovenian: • zapora mrežnične arterije
English: The medicine must be discarded if kept at room temperature for more than two weeks.
Slovenian: Zdravilo, ki je bilo več kot dva tedna shranjeno na sobni temperaturi, morate zavreči.
English: General disorders and administration site conditions Uncommon fatigue, rigors, tenderness, chest pain, influenza like illness
Slovenian: Splošne težave in spremembe na mestu aplikacije občasni utrujenost, mrzlica, bolečnost, bolečina v prsnem košu, gripi podobna bolezen
English: • occlusion of the vein at the back of the eye
Slovenian: • zapora vene v zadnjem delu očesa
English: Less frequently reported serious ocular adverse reactions included endophthalmitis, retinal haemorrhage, vitreous haemorrhage and retinal detachment.
Slovenian: Med manj pogostimi resnimi očesnimi neželenimi učinki so bili endoftalmitis, mrežnična krvavitev, krvavitev v steklovino in odstop mrežnice.
English: - The other ingredients are sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, sodium hydroxide and hydrochloric acid (for pH adjustment) and water for injections.
Slovenian: - Druge sestavine zdravila so natrijev klorid, natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev hidroksid in klorovodikova kislina (za uravnavanje pH) in voda za injekcije.
English: Pegaptanib does not accumulate in the plasma when administered intravitreally every 6 weeks.
Slovenian: Ob intravitrealni uporabi vsakih 6 tednov se pegaptanib ne kopiči v plazmi.